polski | english | login

DOI: 10.18544/PEDM-20.04.0013
Pediatr Endocrinol Diabetes Metab 2014;20,4:136-142

Polymorphisms in the P1 promoter of the IGF-1 gene in children with growth disorders

Justyna K. Broniarczyk, Andrzej Kędzia, Witold Nowak, Łukasz Kościński, Mikołaj Lewandowski, Anna Goździcka-Józefiak

Key words: IGF1, promoter, polymorphism, growth disorders, SNP


Background/Aims. The aim of this study was to associate children’s growth disorders with polymorphisms detected in the P1 promoter region of IGF1 (including SNP and (CA) n microsatellite repeat polymorphism) and IGF1 and IGFPB3 levels. Methods. IGF-1 gene P1 promoter polymorphism was analyzed in DNA obtained from the blood of 51 children with growth disorders and 50 healthy children without growth disorders by means of PCR-SSCP and sequencing. Results. Among children with growth disorders and the control group we found previously described polymorphisms in the P1 promoter of the IGF-1 gene (rs35767, rs5742612) and different genotypes. The frequency of both detected polymorphisms was no significantly different in the study and the control groups. The CA repeat sequence within the group of children in the study ranged from 11 to 21. The most common were homozygote 19/19 (49.02%) and heterozygote 19/20 (27.45%). Our results did not show any association between polymorphisms in the P1 promoter and IGF-1 levels in the serum of children with growth disorders. Conclusions. This study demonstrated that SNP and (CA) n microsatellite repeat polymorphisms by themselves are not the primary regulatory elements of IGF-1 expression. However, our bioinformatics analysis has shown that the (CA) n microsatellite region in the P1 promoter of IGF-1 is able to form DNA loop structures which can modulate transcription.


Insulin-like growth factor 1 (IGF-1) is the major mediator in the growth and development of many tissues in the body. IGF-1 has also been implicated in cancer, diabetic and cardiovascular diseases, and aging. The predominant source of IGF-1 is the liver, which supplies approximately 75% of total circulating IGF-1 for the body; however, tissue-specific expression is also noticeable [1]. Thus, IGF-1 reveals both endocrine and auto/paracrine activity. The actions of IGF1 are modulated by binding proteins (IGFBP1-6), proteases and receptors. Most circulating IGF-1 is bound to IGFBP-3 [2].

The IGF-1 gene is present as a single copy on chromosome 12q22-q24. IGF-1 transcription is controlled by two promoters: P1 and P2 that are located upstream of exon 1 and 2, respectively. The main promoter P1 consists of 1630 nucleotides of regulatory region and 322 nucleotides of 5’UTR of exon 1, which is thought to be necessary for correct and efficient transcription from P1 promoter. The sequence of exon 1 is highly conserved among mammalian species and contains multiple initiation sites and binding sites or regulatory elements for such factors as HNF hepatocyte nuclear factor (HNF1, HNF3), CCAAT/ enhancer binding protein (C/EBP), GATA element, muscle regulator factors (MRFs), cAMP response element (CRE) and prostaglandin [3–8]. However, several polymorphisms have been identified in its 5’ flanking promoter region expanding up to 1630 bp upstream on the transcription initiation site of promoter P1 [9–12]. (CA) n microsatellite repeat polymorphism, comprising a variable length of a CA repeat sequence, is located up to around 600-700 bp upstream of the transcription initiation site. The number of CA repeats ranges between 10 to 25 times. The most common allele (in Caucasian populations) contains 19 repeats [12]. Polymorphism of promoter CA di-nucleotide repeats has been associated with IGF-1 serum level, birthweight and body height and with such diseases as diabetes, cancer and cardiovascular diseases [13–22]. On the other hand, the relation between the CA repeat polymorphism and IGF-1 level depends on race and ethnicity [10–12]. Currently nothing is known about the potential role of these sequences as additional regulators of IGF-1 transcription.

The levels of IGF-1 in tissues and serum vary dramatically and are regulated ontogenetically as well as by multiple hormones and nutritional factors. GH is the most prominent postnatal stimulus for IGF-1 production. IGF-1 transport in serum is mediated mostly by IGFBP3 and the acid labile subunit (ALS), which extend half-life, and may modulate its bioavailability and action. In addition to regulating IGF-1 bioavailability and action, IGFBP-3 also possesses IGF–independent actions, including inhibition of cell growth and induction of apoptosis. It has been proved clinically that measurements of circulating IGFBP-3 and IGF-1 might be useful for the investigation of growth disorders
in children [1, 23].

The aim of this study was to associate children’s growth disorders with polymorphisms detected in the P1 promoter region of IGF-1 (including SNP and (CA) n microsatellite repeat polymorphism) and IGF-1 and IGFPB-3 levels.

Materials and Methods


We examined a group of 51 children (aged 6-13 years) with significant growth retardation (height standard deviation score [HtSDS]-5.4 to -3.6). Parental heights were normal and did not affect growth prognosis. Growth velocity ranged from 0.3 to 2.6 cm/year. Bone age was delayed on average 3.2 years (range 2.6-4.3 years); according to Grelich and Pyle. As a control group, we examined 50 healthy children without growth disorders. In both groups of children, growth retarded and control groups, we excluded GH deficiency, thyroid deficiency and GHR and IGF1R disorders. Blood samples were collected from healthy controls and growth disorder patients to measure the levels of IGF-1, IGFBP-3 and to isolate genomic DNA. This study was approved by the University Ethics Committee (Medical University of Poznan, Poland).

Plasma IGF-1 and IGFBP-3 analysis

Plasma IGF-1 and IGFBP-3 were measured via the radioimmunoassay technique with the use of commercial IGF1 ELISA kits (IDS Ltd, Immunodiagnostic Systems Limited, Boldon, UK) and IGFBP-3: DIAsource IGFBP-3ELISA Kit (DIAsource ImmunoAssays S.A., Nivelles, Belgium). Plasma IGF1 and IGFBP3 levels were on average 110.3 ng/ml and 1385 ng/ml respectively for children with growth retardation and 201.3 and 1506.5 ng/ml for control group. This study was approved by the University Ethics Committee, Medical University of Poznan, Poland.

DNA isolation

Genomic DNA was isolated from the leukocytes (after separation of blood cells from serum) using a Qiamp DNA Blood Mini Kit (Qiagen, Cat. No. 51104) according to the manufacturer’s instructions.

Detection of Polymorphism by SSCP and by Sequencing

Genomic DNA was used for in vitro amplification by PCR with a specific set of primers complementary to the examined region of the IGF-1 gene. Primers were selected from IGF-1 gene promoter sequences taken from the Entrez Gene database as described previously [24].

Four fragments of IGF-1 promoter sequence (region a: between -1404 to -1134nt, region b: between -1115 to -784 nt, region c: between - 633 to -305 nt and region d: between -250 to+49 nt) were amplified by means of a polymerase chain reaction (PCR).

PCR products were analyzed by means of a single strand conformation polymorphism (SSCP) and by sequencing.

Analysis of the CA repeat polymorphism of the IGF-1 promoter genotyping

PCR, using primers designed to amplify the polymorphic (CA)n repeat region of human IGF-1 gene, was performed and analyzed as described previously [25].

Bioinformatics analysis

Transcription factor binding site localization and frequency in the IGF-1 promoter sequence were analyzed using Alibaba 2.1 software http://www.gene-regulation.com/pub/programs/alibaba2/index.html and the TRANSFAC database http://www.gene-regulation.com/pub/databases.html [26, 27].

Secondary structures of DNA were predicted using Mfold software http://www.bioinfo.rpi.edu/applications/mfold [28].

Statistical analysis

For statistical analysis CA-repeats genotyping data as the mean value of the two alleles (biallelic mean) were applied to Student’s t-test. Analyses were carried out by means of the Microsoft Office Excel 2007. Mann Whitney U test was used to assess the difference between SNP genotype groups.


IGF-1 gene P1 promoter polymorphism

IGF-1 gene P1 promoter polymorphism was analyzed in the DNA obtained from the blood cells of 51 children with growth disorders by means of PCR-SSCP and sequencing. Analysis of three regions of the IGF-1 gene P1 promoter from 51 samples showed 2 polymorphisms: RS35767 and RS5742612, previously described in NCBI data. We found 8 genotypes C/T (15.68%), 1 T/T (1.96 %), and 42 C/C (82.35%) for polymorphism RS35767 with localization at -1245nt of the P1 promoter (Figure 1). For polymorphism RS5742612, two heterozygote C/T (3.92%) and 49 (96.08%) homozygote T/T were found. The frequency of both detected polymorphisms was similar in the study and control groups and not significantly different (P>0.05, Mann Whitney U test) (Table 1).

A coexistence of genotype C/T RS35767 and genotype C/T RS 5742612 was found in one subject. One case of coexisting homozygote T/T for RS35767 and heterozygote C/T for RS 5742612 was also observed (Table 1).

The analysis of the CA repeats situated in the P1 promoter region (-1.115 and -784 nt) located at 1kb upstream from the first transcription start site of the IGF-1 gene was also performed. The CA repeat sequences in the study group of children ranged from 11 (1.96%), 17 (0.98%), 18 (4.9%), 19 (72.54%), 20(14.7%), 21 (4.9%) (Table 2). Based on repeated CA nucleotides, several genotypes were distinguished (Table 2). The most common was homozygote 19/19 (49.02%) and heterozygote 19/20 (27.45%) (Table 2). The mean biallelic average lengths were 19,02 ± 0,85 and 19,06 ± 0,75 for children with growth disorders and control group, respectively. These values were no significantly different (P = 0.8, Student’s t test)

Association analysis of IGF-1 and IGFPB-3 levels and detected polymorphisms among children with growth disorders

Among a group of 51 children with growth disorders, we found 9 children with several genetic polymorphisms (Table 4). Our results did not show any associations between IGF-1 and IGFPB-3 levels and detected SNP and CA repeat sequence polymorphisms.

Bioinformatics analysis

Our bioinformatics studies demonstrated that CA repeat regions of the IGF-1 promoter are able to form DNA secondary structures which can serve as modulators of transcription. The CA regions formed DNA loops which may probably serve as a recognition scaffold for transcription factors or other molecules (Fig. 1)

According to the Alibaba 2.1 software, there is one binding site for WT1 in the context of 11 CA repeats in the IGF-1 promoter, two WT1 binding sites for 19 CA repeats and three for 21 CA repeats.

The hypothesis that the microsatellite CA repeat region creates a loop is supported by the DNA secondary structure prediction program Mfold (Figure 1).

Table 1. Frequency of different genotypes

Table 2. Frequency of genotypes based on repeated CA nucleotides situated in the P1 promoter region (-1,115 and-784 nt) in population of children with growth disorders

Fig. 1. Schematic diagram of the human IGF1 promoter showing localization of analyzed RS35767, RS5742612 and CA repeat sequence polymorphism. The pictures also show transcription start sites, the translation start site (ATG), the location and sequences of putative GATA elements and the ERE-like (EREL) sequence.
Numbers are relative to the translation start site (ATG). The white bar represents 59-UTR and the black bar represents a coding sequence. Based on Kang 2012 and Wang L 2000, but modified


Transcriptional control of the IGF-1 gene is complex and depends on: two promoter sites: P1 and P2, multiple transcription factor binding sites, as well as a CA repeat sequence, which is probably involved in transcription modulation. The majority of the control of IGF-1 gene expression occurs at the P1 site. Deregulation of IGF-1 expression may lead to a wide variety of human disorders [1]. Many studies have also reported the association between P1 promoter polymorphisms, IGF-1 blood level and such diseases as diabetes, cancers and cardiovascular diseases [13–22]. In the present study, we examined the association between IGF-1 P1 promoter polymorphisms, IGF-1 levels and growth disorders in children.

Among the studied children with growth disorders we found two previously described polymorphisms, RS35767 and RS5742612, [22] and 8 different genotypes. IGF-1 gene polymorphism genotype distribution between the study group and the control group of children was not statistically different.

Fig. 2. DNA secondary structure prediction of the IGF1 promoter microsatellite region by means of M fold software. DNA secondary structure for 11 CA repeats (A), 19 CA (B) and 21CA repeats (C)

In the study group, the most frequent allele of the CA repeat sequence polymorphism contains 19 CA repeats and homozygote carriers. 19 CA repeats were found in 49% of the studied children. The length of the repeat sequence in children with growth disorders ranged from 11 to 21. A similar distribution of CA polymorphism was observed among the control group. The 19 CA repeats allele is most frequent in both Caucasians and African-Americans [12]. Akin et al. indicated that alleles with 20 CA of the IGF-1 promoter have higher circulating IGF-1 levels than others in patients with acromegaly [14]. Other studies have indicated that carriers of the allele with 19CA repeats and/or 20 CA repeats of the IGF-1 promoter have higher, lower or similar circulating IGF-1 levels than non-carriers of these alleles [29]. No effect on stature of IGF-1 gene polymorphisms was demonstrated by Tekcanet al [30]. This study has reported conflicting results on the associations between P1 polymorphisms and IGF-1 levels in blood serum. We observed that some of the children with growth disorders also had significantly higher levels of IGF-1 and IGFBP-3. IGFBP-3 regulates IGF-1 availability and function.

IGFBP-3 also possesses IGF-independent actions, including inhibition of cell growth and induction of apoptosis (31). All this data suggest that detected IGF-1 P1 promoter polymorphisms by themselves are not the primary regulatory element of IGF-1 expression. Probably, additional not well known factors, such as the combination of genetic, nutritional, and environmental factors, may be involved in IGF-1 expression regulation.

Our bioinformatics studies showed that the CA repeat region of the P1 promoter of IGF-1 is able to form DNA loop structures which can probably serve as a transcription modulator. Such DNA loop structures are formed for example in the promoter region of Bcl2 (32) or in RNA of protonated adenine-cytosine base pairs that contribute to structural stabilization and are important protein recognition sites [33–35]. Therefore, we suggest that the CA repeat region of IGF-1 may probably serve as a recognition site for the WT1 transcription factor or other molecules and might have an influence on IGF-1 promoter activity and the blood levels of IGF-1. However, further studies are needed to prove this hypothesis. WT1 is a transcription factor acting as a tumor suppressor protein regulating growth and differentiation. Vasileiou et al. indicated that WT1 gene expression is implicated in altered IGF-1 and IGF-2 activity and mutations of the gene may lead to overgrowth during fetal life [35]. On the other hand, most biological actions of IGF-1 are mediated by the IGF-1 receptor which is associated with ras/raf MAPK and phosphatidylinositol 3 kinase signaling cascades. In vitro studies confirmed the unequivocal correlation between the IGF-1 receptor and WT1, suggesting that expression of the WT1 protein likely suppresses IGF-1 receptor activity to a different extent [36].

Changes in the numbers of CA repeats as well as aberration in WT1 expression might have an influence on IGF-1 promoter activity; however, further studies are needed to prove this hypothesis. Hewitt et al., by means of a chromatin immunoprecepitation assay, indicated binding of the estrogen receptor alfa at the human IGF-1 promoter, where there are no estrogen response element (ERE) sequences present [37]. Telgmann et al [8] described, in the distal region of the P1 IGF-1: -1411 C>T site, a transcriptionally active enhancer containing a cluster of several partly overlapping TFBSs(AP1, HNF3, C/EBP) capable of integrating transcriptionally active stimuli from different signal transduction pathways in a cell type-specific manner. IGF-1 promoters also respond to a diet and caloric intake [38]. Maternal nutrient deprivation results in intrauterine growth restriction of the offspring, and neonates from such deprivation have deficiencies in postnatal circulating IGF-1. Additionally, CpG islands are methylated [39]. These epigenetic modifications of the IGF-1 promoter repress transcription. Further studies on a large population are required to confirm these data.

Declaration of interest

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.


This project was supported by grant number NN407200037 from the Ministry of Science and Higher Education in Poland.


1. Monzavi R, Cohen P: IGFs and IGFBPs: role in health and disease. Best practice and research. Clin Endocrinol Metab 2002; 16(3): 433-447.

2. Jogie-Brahim S, Feldman D, Oh Y: Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human disease. Endocr Rev 2009; 30(5):417-37.

3. McLellan AS, Kealey T, Langlands K: An E box in the exon 1 promoter regulates insulin-like growth factor-I expression in differentiating muscle cells. Am J Physiol Cell Physiol 2006; 291(2): C300-7.

4. An MR, Lowe WL Jr: The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. Mol Cell Endocrinol 1995;114(1-2): 77-89.

5. Mittanck DW, Kim SW, Rotwein P: Essential promoter elements are located within the 5’ untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol 1997; 126(2): 153-63.

6. Wang L, Wang X, Adamo ML: Two putative GATA motifs in the proximal exon 1 promoter of the rat insulin-like growth factor I gene regulate basal promoter activity. Endocrinology 2000: 141: 1118-1126.

7. Wang L, Adamo ML: Cyclic adenosine 3’5’-monophosphate inhibits insulin-like growth factor I gene expression in rat gloma cell lines: evidence for regulation of transcription and messenger ribonucleic acid stability. Endocrinology 2001; 142: 3041-50.

8. Telgmann R, Dordelmann C, Brand E, Nicaud V, Hagedorn C, Pavenstadt H, Cambien F, Tiret L, Paul M, Brandt-Herrmann SM: Molecular etic analysis of a human insulin-like growth factor 1 promoter P1 variation. FASEB J 2009; 23: 1103-1313.

9. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83(7): 2286-90.

10. Xie L, Gong Y, Lian S, Yang Y, Gao S, Xu S, Zhang Y: A microsatellite polymorphism in IGF 1 gene promoter and longevity in a Han Chinese population. BMC Res Notes 2010; 3: 55-61.

11. Jayanthiny P, Tennekoon KH, Karunanayake EH, Kumarasiri JM, Wijesundera APDS: Di-nucleotide repeat polymorphisms of the insulin-like growth factor 1 gene and their association with IGF-1, Insulin-like growth factor binding protein-1 and birth size in a Sri-Lanka Cohort. Neonatology 2011; 100: 37-43.

12. Rietveld I, Janssen Jam JL, Van Duijn CM, Lamberts SW: A polymorphic CA repeat in the promoter region of the insulin-like growth factor-I (IGF-I) gene. Eur J Epidemiol 2003; 18: 191-193.

13. Euser AM, Finken MJ, Kharagjitsinh AV, Alizadeh BZ, Roep BO, Meulenbelt I, Dekker FW, Wit JM: IGF 1 promoter polymorphism and cranial growth in individuals born very preterm. Horm Res Paediatr 2011; 76(1): 27-34.

14. Akin F, Turgut S, Cirak B, Kursunluoglu R: IGF(CA)19 and IG-FBP-3-202A/C gene polymorphism in patients with acromegaly. Growth Horm IGF Res 2010; 20(6): 399-403.

15. Chen X, Guan J, Song Y, Chen P, Zheng H, Tang Ch, Wu Q: IGF-I(CA) repeat polymorphism and risk of cancer : a meta–analysis. J Hum Genet 2008; 53(3): 227-38. i

16. Zou YF, Wang F, Feng XL: The association between IGF 1 CA repeat polymorphisms and breast cancer risk: appraisal of a recent meta-analysis. Breast Cancer Res Treat 2011; 128(3): 913-5.

17. Sarkissyan M, Mishra DK, Wu Y, Shang X, Sarkissyan S, Vadgama YV: IGF gene polymorphisms and breast cancer in African-American and Hispanic women. Int J Oncol. 2011; 38(6): 1663-73.

18. Keku TO, Vidal A, Oliver S, Hoyo C, Hall IJ, Omofoye O, McDoom M, Worley K, Galanko J, Sandler RS, Millikan R: Genetic variants in IGF-I, IGF-II, IGFBP-3 and adiponectin genes and colon cancer risk in African Americans and Whites. Cancer Causes Control 2012; 23(7): 1127-38.

19. Kostek MC, Devaney JM, Gordish-Dressman H, Harris TB, Thompson PD, Clarkson PM, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Seip RL, Garcia M, Li R, Zmuda JM, Delmonico MJ, Kanaya A, Hoffman EP: A polymorphism near IGF 1 is associated with body composition and muscle functions in women from the health, aging, and body composition study. Eur J Appl Physiol 2010; 110(2): 315-24.

20. Milletta MC, Scheidegger UA, Giordano M, Bozzola M, Pagani S, Bona G, Dattani M, Hindmarsh PC, Petkovic V, Oser-Meier M, Fluck CE, Mullis PE: Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and –202A/C IGF binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency. Clin Endocrinol (Oxf) 2012; 76(5): 683-90.

21. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: A polymorphism in the gene for IGF-1: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50: 637-642.

22. Burchardt P, Gozdzicka-Jozefiak A, Zurawski J, Nowak W, Durzynska J, Link R, Grotowski T, Siminiak T: Are elevated levels of IGF-1 caused by coronary arteriesoclerosis? Protein J 2010; 29(8): 538-44.

23. Vottero D, Guzzetti C, Loche S: New aspects of the physiology of the GH-IGF 1 axis. Endocr Dev 2013; 24: 96-105.

24. Obrepalska-Steplowska A, Kedzia A, Goździcka-Józefiak A, Jakubowicz M, Korman E: Analysis of the human growth hormone receptor and IGF-I coding sequences in children with growth disorders. J Pediatr Endocrinol Metab 2003; 16(6): 819-25.

25. Pacholska-Bogalska J, Jozefiak A, Nowak W, Kedzia W, Kwasniewska A, Gozdzicka-Jozefiak A: Association of the IGF-1 promoter P1 polymorphism with risk of cervical cancer. Eur J Gynaecol Oncol 2011; 32(4): 393-8.

26. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol 2002; 2(1): S1-15.

27. Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Pruess M, Reuter I, Schacherer F. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Research 2000 28 316-319.

28. Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2000; 28(1): 316-9.

29. Li L, Cicek MS, Casey G, Witte JS: No association between genetic polymorphisms in IGF-I and IGFBP3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(3): 497-8.

30. Tekcan D, Bas F, Ataler F, Avdin BK, Akan G, Tarhan T, Bunda R, Darendeliler F: No effect of the IGF-1 gene rs35767 anf rs17032362 polymorphisms in the etiology of idiopathic short stature. Exp Clin Endocrinol Diabetes 2012; 120(7): 395-400.

31. Martin JL, Baxter RC: Signaling pathways of insulin-like growth factors (IGFs) and IGFBP3. Growth Factors 2011; 29(6): 235-44.

32. Kendrick S, Akiyama Y, Hecht SM, Hurley LH: The i-motif in the bcl-2 P1 promoters forms an unexpectedly stable structure with a unique 8:5:7 loop folding pattern. J Am Chem Soc 2009; 131(48): 17667-76.

33. Tokuda N, Sasai M, Chikenji: Roles of DNA looping in enhancer-blocking activity. Biophys J 2011; 100(1): 126-34.

34. Legault P, Pardi A: 31P chemical shift as a probe of structural motif in RNA. J Magn Reson B 1994; 103(1): 82-6.

35. Jang SB, Hung L, Chi Y, Holbrook EL, Carter RJ, Holbrook SR: Structure of an RNA internal loop consisting of tandem C-A+ base pairs. Biochemistry 1998; 37: 11726-11731.

36. Werner H, Shen-Orr Z, Rauscher III FJ, Morris JF, Roberts JrCT, LeRoith D.1995 Inhibition of cellular proliferation by the Wilms’tumor suppressor WT1 is associated with suppression of insulin-like growth factor 1 receptor gene expression. Molecular and Cellular Biology 1995 15 3516-3522.

37. Hewitt SC, Li Y, Korach KS: Estrogen-mediated regulation of IGF 1 transcription and uterine growth involves direct binding of estrogen receptor alpha to estrogen-responsive elements. Mol Cell Biol 1995;15(7): 3516-22.

38. Xie L, Jiang Y, 0uyangP, Chen J, Doan H, Herndon B, Sylvester JE, Zhang K, Molteni A, Reichle M, Zhang R, Haub MD, Baybutt RC, Wang W: Effects of dietary calorie restriction or exercise on the PI3K Ras signaling pathways in the skin mice. J Biol Chem 2007; 282(38): 28025-35.

39. Schlabritz-Loutsevitch NE, Hubbard GB, Han V, Nygard K, Cox LA, McDonald TJ, Nathanielsz PW: Effects of maternal global nutrient restriction on fetal baboon hepatic insulin-like growth factor system genes and gene products. Endocrinology 2009; 150(10): 4634-42.

40. Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bae I: BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Cell Death Dis 2012; 3: e336.

advanced search »

Article in databases

DOI: 10.18544/PEDM-20.04.0013
PUBMED: view

Similar articles

Growth hormone therapy in a girl with Turner syndrome and diabetes type ...

Insulin-like growth factor-1 (IGF-1) – structure and the role in the hum ...

Yeast-like fungi in the gastrointestinal tract in children and adolescen ...

Silver-Russell Syndrome – Part I: Clinical Characteristics and Genetic B ...

Suspicion of anorexia nervosa as a cause of delayed diagnosis of brain t ...

Pediatric Endocrinology Diabetes and Metabolism

2018; 24, 1: 1-51
2017; 23, 4: 169-222
2017; 23, 3: 117-168
2017; 23, 2: 59-116
2017; 23, 1: 1-58
2016; 22, 4: 133-180
2016; 22, 3: 81-132
2016; 22, 2: 43-79
2016; 22, 1: 1-42
2015; 21, 4: 149-191
2015; 21, 3: 97-148
2015; 21, 2: 51-96
2015; 21, 1: 1-50
2014; 20, 4: 131-182
2014; 20, 3: 83-130
2014; 20, 2: 35-82